Tuesday 2 July 2019
Investor Ideas #Potcasts: #Cannabis News and #Stocks on the Move (TSXV: $KHRN.V) (OTCQB: $KHRNF), (CSE: $MYM.C) (OTCBB: $MYMMF) (NASDAQ: $OGI)
Investor Ideas #Potcasts: #Cannabis News and #Stocks on the Move
(TSXV: $KHRN.V) (OTCQB: $KHRNF), (CSE: $MYM.C) (OTCBB: $MYMMF)
(NASDAQ: $OGI)
Also featured in today’s potcast- (CSE: $HUGE.C) (OTCQB: $FSDDF)
(TSXV: $OGI.V), (TSX: $IN.TO) (OTCQX: $IMLFF)
Delta, Kelowna, BC –July 2,
2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source
covering leading sectors including marijuana and hemp stocks and its potcast
site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/07021KHRN-MYM-OGI.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com “potcasts”,
looking at cannabis news, stocks to watch as well as insights from thought
leaders and experts.
Today we are looking at a few early
announcements.
But first, Health Minister Simon Harris signed
legislation which will now allow Irish citizens
access to cannabis-based products for medical use on a pilot basis for five
years. The new Medical
Cannabis Access Programme allows medical
consultants to prescribe medicinal cannabis of a standardised quality to
patients who have failed to respond to standard treatments.
Minister Harris first
proposed the programme two years ago, but its passage through the Dáil was delayed amid problems finding a
quality-assured supplier of medicinal cannabis able to export its products to
Ireland.
Earlier this year, it was confirmed that a
supplier had been identified and the legislation was finally signed this
morning.
The new scheme will facilitate access to
medical cannabis for patients with the following conditions if they have failed
to respond to standard treatments:
● Spasticity associated with multiple
sclerosis
● Intractable nausea and vomiting associated
with chemotherapy
● Severe, refractory (treatment-resistant)
epilepsy
Commenting on the launch today, Mr Harris
said: "It is important to state that there are no plans to legalise
cannabis in this country.
"The purpose of this programme is to
facilitate compassionate access to cannabis for medical reasons, where
conventional treatment has failed.
"Ultimately it will be the decision of
the medical consultant, in consultation with their patient, to prescribe a
particular treatment, including a cannabis-based treatment, for a patient under
their care."
Previously, there were no medical cannabis
products available in Ireland and many sufferers were forced to spend thousands
each year to access cannabis-based treatments in countries such as the
Netherlands.
The new legislation means that commercial
operators whose cannabis products meet the specified requirements will be able
to supply products to the Irish market.
The Medical Cannabis Access Programme will
operate on a pilot basis for five years before a review in 2024.
Khiron Life
Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF), commented on the EU-Mercosur Trade Agreement announced
between the European Union and Mercosur, the Latin American trading block made
up of Argentina, Brazil, Uruguay and Paraguay. Khiron is active among Mercosur
jurisdictions with a recently completed acquisition of NettaGrowth
International, a cannabis company based in Uruguay.
The
trade deal between the European Union and Mercosur announced on June 28, 2019
at the G20 Summit in Japan, which is subject to ratification by member
countries, establishes a trade framework for goods and services, including
pharma and medical products, covering nearly 780 million consumers, making it the
largest in the world in terms of population, and with an estimated trade in
goods of 88 Billion Euros (Source: European Commission).
Alvaro
Torres, Khiron CEO and Director, comments "As we build Khiron's dominant
position in Latin America and Mercosur markets through our operations in
Uruguay, we welcome this trade deal as it strengthens our ability to now
directly supply the European medical cannabis market. This significant
milestone is another step towards a globalized medical cannabis trade network
where Latin America, with its strategic location, many natural advantages and
regulatory leadership, will continue to play a significant part."
Khiron
announced completion of the acquisition of NettaGrowth International on June
19, 2019. NettaGrowth, and its wholly-owned subsidiary Dormul S.A. is a
Uruguayan company that has obtained one of the first licences to produce and
export medical cannabis with THC for commercialization in Uruguay, and is
positioned to serve Brazil and the growing Latin American market as part of the
Mercosur trading block, adopting the Company's scalable model as markets
develop.
MYM Nutraceuticals
Inc. (CSE: MYM) (OTCBB: MYMMF) announced that its subsidiary in Colombia, Colombia
Organica S.A.S, has signed agreements in principle to cultivate both THC and
CBD-rich cannabis with independent farmers for an initial five acres.
Cannabis
will be cultivated by farmers who will be licensees under the existing Colombia
Organica cannabis cultivation licenses. The first crops cultivated on the
initial five acres will function as test crops with the intention to add
subsequent acreage. The climate in Colombia is ideal for cultivating cannabis,
with the growing season being year-round it's possible to harvest three crops
of THC or CBD-rich cannabis annually.
"Our
team in Colombia has begun to execute on our plan to cultivate both THC and
CBD-rich cannabis in South America," said Howard Steinberg, CEO of MYM.
"The strategy of extending our licenses to neighbouring farmers to
cultivate cannabis will serve to increase our biomass supply that we intend on
processing and exporting to the global market."
Colombia
Organica is committed to extending its licenses to the independent farmers for
an initial period of five years. The farmers will be responsible for all costs
associated with cultivation from seed to sale. Colombia Organica agrees to
purchase the harvested biomass at a price to be determined at the time of
delivery based on the average market price at that time.
MYM
is currently finalizing the closing documents that will see its own 80% of
Colombia Organica.
Organigram Holdings
Inc. (NASDAQ: OGI) (TSXV: OGI), the parent company of Organigram Inc., a
leading licensed producer of cannabis, announced today it will report its third quarter earnings
results for its fiscal year ended August 31, 2019 on Monday, July 15, 2019
before market open.
The
Company will host a conference call to discuss its third quarter 2019 earnings
results at 8am EST.
A replay of the webcast will be available
within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the
call.
FSD Pharma Inc. (CSE:HUGE) (OTCQB:
FSDDF) and Prismic Pharmaceuticals Inc., a
U.S.-based specialty R&D pharmaceutical company, have
announced that, on June 28, 2019, they finalized
the acquisition by FSD Pharma of all of the issued and outstanding securities
of Prismic for an aggregate purchase price of approximately US$17.5 million,
satisfied by the issuance of approximately 102.7 million Class B subordinate
voting shares in the capital of FSD Pharma at a deemed price of CAD$0.2275 per
FSD Share. In addition, FSD Pharma has agreed to assume approximately US$3.05
million of outstanding Prismic long- and short-term liabilities.
FSD Pharma will continue to be led by
Raza Bokhari, MD, executive co-chairman and CEO. Zachary Dutton, co-founder of
Prismic, will continue to serve as the CEO of Prismic, reporting to Edward
Brennan, Jr. MD, FACS, president of the FSD Biosciences Division.
Peter Moriarty, co-founder and previous
chairman of the board of Prismic, has been named chairman of the newly-formed
FSD BioPharmaceutical Industry Advisory Board.
Bokhari stated, “On behalf of the FSD
Pharma shareholders and Board of Directors, it is with immense pleasure that I
welcome Prismic shareholders and stakeholders to the FSD Pharma family. Over
the past several weeks, Dr. Brennan and our M&A team have worked very
closely with the Prismic leadership to finalize this transaction under budget
and ahead of schedule. I must commend Dr. Brennan on his laser sharp focus and
attention to detail and I must also express my special gratitude to Zach Dutton
and Peter Moriarty for their efforts in resolving some outstanding issues to
close the transaction.”
Bokhari continued, “The Prismic
acquisition represents strategic depth in the vision and mission of FSD Pharma
and signals a paradigm shift in the overall outlook of the company. We are
relying heavily on the expertise of Dr. Brennan, who is a seasoned
pharmaceutical industry veteran with substantial experience from working at
Glaxo Smith Kline and Johnson & Johnson to navigate us through the various
stages of the FDA approval process for drug development, with the goal of
eventually making synthetic cannabinoid prescription medications available for
commercial use to help alleviate the pain and suffering of patients. We are
confident, Peter Moriarty, another well-known pharmaceutical industry veteran,
who was also one of the founders of Shire Pharmaceuticals, will make a
meaningful contribution to the FSD Pharma story as the chairman of the
BioPharmaceutical industry advisory board.”
InMed Pharmaceuticals Inc. (TSX:IN) (OTCQX:IMLFF), a
biopharmaceutical company developing a proprietary biosynthesis technology for
cannabinoid-based pharmaceuticals to treat severe diseases, today
announced the appointment of Catherine Sazdanoff,
JD, to its Board of Directors.
Ms. Sazdanoff joins InMed's Board with 35
years of experience in the healthcare industry. She held various global VP
roles in business development and corporate development at Takeda
Pharmaceuticals, which she joined in 2006. Prior to Takeda, Ms. Sazdanoff
served in senior global legal and pharmaceutical business roles at Abbott
Laboratories since 1984, including litigation, international commercial and
transactional legal roles, marketing, and business development. At both
companies, she completed numerous collaborations and transformational M&A
transactions, including Abbott's acquisition of Knoll Laboratories (including
the mega-blockbuster drug Humira®), and Takeda's acquisition of Millennium
Pharmaceuticals and Nycomed S.A.
Ms. Sazdanoff is an independent director
of the Board of Meridian Bioscience,
Inc. (NASDAQ:
VIVO). She is currently President and CEO of
Sazdanoff Consulting LLC, where she acts as Business Advisor to Strata
Oncology, Inc., a private precision oncology company, and works with other
healthcare companies on strategy and corporate/business development. Ms.
Sazdanoff has a BA in English from the University of Notre Dame, and a JD from
Northwestern University School of Law.
"We are enthusiastic to welcome
Catherine to our Board of Directors at an exciting time in the Company's
evolution," commented Eric A. Adams, President and Chief Executive
Officer. "Her diverse business development and legal experience, built
from over 35 years in the pharmaceutical industry, will be important as we
accelerate the development of our therapeutic pipeline and scale-up our
innovative biosynthesis platform technology. Importantly, Catherine's rich
experience in pharma deal making will be highly beneficial to InMed as our
assets mature and we begin strategizing about potential transactions."
"InMed has unique opportunities to
bring significant medical advances to important patient populations with its
differentiated cannabinoid-based therapeutic pipeline and novel biosynthesis
manufacturing technology," stated Ms. Sazdanoff. "I am delighted to
join the team and look forward to working closely with the Company's management
as InMed drives towards long-term value creation."
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
Monday 1 July 2019
Recent #CBD / #Cannabis Acquisitions (OTC: $SIML) (TSX: $WEED.TO) (NYSE: $CGC) (CSE: $CRFT.C) (CSE: $IAN.C) (OTCQX: $ITHUF)
Recent #CBD / #Cannabis
Acquisitions (OTC: $SIML) (TSX:
$WEED.TO) (NYSE: $CGC) (CSE: $CRFT.C) (CSE: $IAN.C) (OTCQX: $ITHUF)
Point Roberts WA,
Delta BC – July 1, 2019 - Investorideas.com, a leading investor news resource covering
hemp and cannabis stocks releases a multi-media snapshot reporting on recent
acquisitions in the CBD cannabis space.
Viridian’s
Deal Tracker recently noted, “Acquisitions of companies in the hemp sector
accelerate worldwide as industrial and consumer hemp/CBD markets develop.”
Driving
the acquisition flurry; the collective market for CBD sales is expected to
exceed $20 billion in the United States by 2024, according to BDS Analytics and
Arcview Market Research.
Aiming to capitalize on this, Simlatus Corporation
(OTC PINK:SIML), a holding
company focused on opportunities in the cannabis space just announced that the
Company is cleaning up corporately to be better positioned for acquisitions in
the future.
Read this in full at https://www.investorideas.com/news/2019/cannabis/07011Stocks-Acquisitions.asp
From the news - “During the
past several months the Company has retired and returned to treasury $2.7M in
Convertible Debt using its cash reserves to quarantine toxic conversions, stock
dilution and preserve its equity.“
Continued: Richard Hylen, Chairman
and CEO stated “Our shareholders and management team have been on an impressive
run ever since the company expanded its footprint into the cannabis sector with
our most recent acquisition of Proscere Bioscience. With this acquisition, the
company gained access to a cold-water CBD extraction Technology that presents
an exciting opportunity on revenue generation. With the acquisition, the
company has gained access to a valuable asset capable of strengthening its
revenue base, with a current $2.8M in its first purchase order, and commitments
of $275M over the next 5 years. The company has already set sights on Canada,
USA, and Europe as it embarks on an aggressive commercialization drive for the
cold-water CBD extraction systems.”
Cannabis leader, Canopy Growth Corporation (TSX:WEED) (NYSE:CGC) is also
completing an acquisition in extraction technology, announcing on June 26th that it has completed a transaction to acquire Saskatoon-based
bio-product extractor KeyLeaf Life Sciences, related entities and intellectual
property. “Canopy Growth has been
working closely with KeyLeaf – formerly known as POS Bio-Sciences – as a
trusted partner building out extraction processes and technology for the past
year as it refines its scale extraction model for Canadian and global markets.
As previously disclosed, Canopy Growth assumed control of KeyLeaf for
accounting purposes in November 2018. As such, KeyLeaf’s financial results were
consolidated in the Company’s fiscal 2019 financial statements. Through the
transaction, the Company is acquiring a large-scale Canadian extraction
facility as well as an extraction-related facility in the United States to
support the Company’s US CBD expansion.”
Continued: “With over 45 years of
experience in the canola, nutraceutical, cosmetic and bio-product industries,
KeyLeaf is a recognized leading authority with significant intellectual
property relating to plant-based extraction and ingredients. The extensive
experience of KeyLeaf’s chemists, engineers, and operators will remain within
the organization to further refine the cannabinoid extraction process and will
support Canopy Growth in the design, training, oversight, and implementation of
additional extraction sites around the world.”
Continued: “KeyLeaf has been working
closely with Canopy Growth over the past year to retrofit its Saskatchewan
facility to advance technology development and commercialization, in order to
process hemp and cannabis biomass, and to conduct pre- and post-extraction
processes. It is anticipated the
facility, which is currently in the Health Canada licensing process, will be
able to process up to 5,000 kg of input materials daily when operational.”
Continued: “Canopy Growth intends to
leverage this facility, along with other owned and partner extraction options,
to process its over 5,000 acres of Canadian CBD hemp production, over 160 acres
of outdoor cannabis production, as well as any extraction materials outputted
from its over 4 million square feet of greenhouse growing operations. Then it’s off to Smiths Falls to produce the
best possible, IP-protected products out there!”
Looking at other recent acquisition news in the sector,
Pasha Brands Ltd. (CSE: CRFT) (OTC:CRFTF), Canada's
largest craft cannabis brands organization, announced on June 24th the acquisition of the CBD Therapeutics brand – a leading
pre-legalization manufacturer and purveyor of cannabidiol (CBD) product based
in British Columbia.
Continued: “Since its
inception, CBD Therapeutics has supplied solvent-less full spectrum and
isolated CBD formulations to the pre-legalization market throughout Canada, and
increased access to both products and education. Since ceasing sales on October
17, 2018, CBD Therapeutics has been preparing to enter the regulated framework.
Pasha has acquired all of the brand's trademarks, names and intellectual
property and will re-launch the brand in the Canadian regulated market in the
very near future.”
Continued: "Joining
Pasha Brands is yet another step forward in our mission of making CBD products
more accessible," said James Whitehead, CEO of CBD Therapeutics.
"Working with a collective of smart, like minded individuals and brands
will help open opportunities for CBD Therapeutics and aid our growth. It
already has."
Finalizing a previously announced acquisition,
iAnthus Capital Holdings, Inc. (CSE: IAN, OTCQX: ITHUF), which owns,
operates and partners with best-in-class regulated cannabis operations across
the United States, announced on June 28th that its US subsidiary has closed the previously
announced acquisition of CBD For Life, a top-ranked, national CBD brand in the
US.
Continued: “CBD For Life has
experienced accelerating revenue growth, from both existing customers and new
account additions—representing approximately 50% quarter over quarter growth.
CBD For Life's products are sold directly to consumers online at
www.cbdforlife.us as well as in over 1,000 retail locations in 46 states, with
a dedicated sales channel working with national retailers to on-board new
locations weekly. CBD For Life's roster of national retailers include Urban
Outfitters, Paper Source, Of a Kind, Olympia Sports, and Weis Markets, with
others soon to be announced. Since announcing the Urban Outfitters relationship
in mid-April 2019, the retailer has expanded the lineup of CBD For Life
products it carries and the number of retail locations in which it offers them.
CBD For Life's CBD-infused wellness, self-care, and beauty products have been
featured in a wide range of cable, online, and print publications—including on
NBC's Today Show and Telemundo47.”
Continued: “According
to industry experts, U.S. retail sales of CBD consumer products are estimated
to have been between $600 million and $2 billion in 2018. As a growing number
of CBD brands and product types become increasingly available through diverse
retail channels, the CBD market is projected to generate $16 billion in U.S.
retail sales by 2025. Research has shown that nearly 7% of the U.S. population
in January of 2019 reported using CBD as a supplement, and that number is
expected to grow to at least 10% by 2025.”
“CBD sales have
exploded in the past several months, but there’s still a long way to go when it
comes to consumer, retailer, and manufacturer knowledge,” said Jessica Lukas,
Vice President of Consumers Insights at BDS Analytics. “56 percent of adults
21+ do not know or are confused about the differences between THC and CBD.”
As the consumer
matures, so will the industry and the hunt for acquisitions will continue to
find the best in breed within the sector.
Read the full article/snapshot on
Investorideas.com
For investors
following cannabis stocks, Investor Ideas has created a stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX
Marijuana/Hemp Stocks
About Investorideas.com - News that Inspires
Big Investing Ideas
Investorideas.com is a recognized news source
publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about
cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water,
renewable energy and more . Investorideas.com original branded content includes
the daily Crypto
Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis
News and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI Eye Podcast and column covering developments in AI.
Follow us on Cannabis Social Media
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure is posted for each compensated news release, content published
/created if required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions.
Disclosure: this news
article SIML is a paid for service( two thousand ) on Investorideas.com - third party . More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global
investors must adhere to regulations of each country. Please read
Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Contact Investorideas.com
800-665-0411
Get more Marijuana,
hemp & cannabis stock investor ideas-
news, articles, podcasts and stock directories
Subscribe to:
Posts (Atom)
Stocks to Watch Battling the Opioid Epidemic; Stocks Mentioned in this article: Greenlane Holdings, Inc. (NASDAQ: $GNLN), Safe Supply Streaming Co Ltd. (CSE: $SPLY.CN), Nutriband Inc. (NASDAQ: $NTRB), QuidelOrtho Corporation (Nasdaq: $QDEL), Emergent BioSolutions Inc. (NYSE: $EBS)
Stocks to Watch Battling the Opioid Epidemic ; Stocks Mentioned in this article: Greenlane Holdings, Inc. (NASDAQ: $GNLN), Safe Supply St...
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ... -
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Dixie Brands (CSE: $DIXI_U.C) (OTC: $DXBRF), Khiron Life Sciences (T... -
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...